Merck Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge

 
 

   Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnosis and treatment for lung cancer patients   

 

Merck Canada and MaRS Discovery District (MaRS) are proud to launch the Lung Cancer Innovation Challenge . The competition challenges Ontario -based innovators to identify, implement and scale solutions that can enhance an Ontario lung cancer patient's journey by seeking to reduce the length of time between diagnosis and treatment for lung cancer patients, and enable improved treatment outcomes, especially for priority patient groups such as rural and lower socioeconomic populations in Ontario . Financial prizes will be awarded to the winners of the challenge. In addition, the winners may have the opportunity to collaborate on future projects with Merck Canada. Of the four most common cancers, lung cancer, has the lowest survival rate, regardless of stage at diagnosis. 1 It is estimated that 29,800 new lung cancer cases would be diagnosed in 2020 across Canada with almost 40 per cent of those cases residing in Ontario alone. 2,3 The ability for lung cancer patients to receive initial access to primary care and the proper treatment at the right time is dependent upon a number of different factors that touch on the patient, their circle of care, and the broader health system.

 

 

  Merck Logo (CNW Group/Merck) 

 
 

"We play an important role within Canada's healthcare environment, and we are very committed to helping solve key issues which patients are facing today. Our Life Sciences sector is one of the most innovative sectors imaginable and is key to tackling some of society's biggest health challenges. Innovative partnerships and joint initiatives, like this one with MaRS, are allowing us to collaborate and to tap into some of Ontario's brightest minds in order to bring new, invaluable solutions to people facing cancer," says AnnA Van Acker , President and Managing Director of Merck Canada. "The majority of lung cancer cases are diagnosed at Stage 4 and the disease often rapidly progresses to a point where appropriate treatment is no longer an option. The Lung Cancer Innovation Challenge provides an exciting opportunity to go above and beyond and to find much needed ways to help shorten the time gap between diagnosis and treatment, thereby potentially improving patient outcomes, individually and collectively."

 

The challenge kicks off today, January 20 , with a virtual launch event at 11 a.m. EST featuring a panel discussion on the barriers and opportunities associated with the diagnosis and treatment of lung cancer. Panelists representing a diverse range of perspectives across the healthcare system — including patients, healthcare providers and other innovators — will share their experiences and speak to the additional challenges posed by the COVID-19 pandemic.

 

"Fighting lung cancer during a pandemic means reduced access to primary care, diagnosis and screening. It's also a very lonely process with tightened restrictions on visitor policies," says Alex Ryan , SVP, Partner Solutions at MaRS. "By partnering with Merck Canada, we will help foster innovative solutions that diffuse some of the COVID-19 complexities lung cancer patients encounter while strengthening and building long-term resiliency in Ontario's health care system."

 

"I'd like to congratulate Merck Canada and MaRS on the launch of this joint initiative," said Nina Tangri , Parliamentary Assistant to the Minister of Economic Development, Job Creation, and Trade. "Now more than ever, we need innovation and new ideas to better our healthcare system. I look forward to seeing the novel and life-changing solutions that Ontario's innovators submit to the challenge to help patients and families."

 

The challenge will run until March 25, 2021 , and the grand-prize winner will receive a $100,000 prize with $50,000 going to the runner-up prize winner. Winners will be announced by April 28, 2021 . Please go here for more information or to register for the launch event.

 

  About Merck  
For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.

 

  About MaRS
MaRS is North America's largest urban innovation hub. A registered non-profit, MaRS supports high-growth startups and scale-ups tackling key issues in health, cleantech, fintech and other sectors. In addition, MaRS convenes all members of the tech ecosystem to drive breakthrough discoveries, grow the economy and make an impact by solving real problems for real people — in Canada and around the world.

 
 
     
 

   References   

 
 

  _______________________________  

 
 

   1 Ontario Cancer Statistics 2018 — Cancer Care Ontario  

 
 

   2 Ontario Cancer Statistics 2018 — Cancer Care Ontario  

 
 

   3 Target Wait Times for Cancer Surgery in Ontario, 2016 — Cancer Care Ontario  

 
 
 

 

 
 
 

SOURCE Merck

 

 

 

 Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/January2021/20/c1543.html  

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×